NK8 Stock Overview NuVasive, Inc., a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
NuVasive, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for NuVasive Historical stock prices Current Share Price US$36.80 52 Week High US$48.00 52 Week Low US$33.80 Beta 1.07 1 Month Change n/a 3 Month Change n/a 1 Year Change -12.38% 3 Year Change -14.02% 5 Year Change -37.81% Change since IPO 315.82%
Recent News & Updates
NuVasive, Inc.(NasdaqGS:NUVA) dropped from NASDAQ Composite Index Sep 06
Globus Medical, Inc. (NYSE:GMED) completed the acquisition of NuVasive, Inc. (NasdaqGS:NUVA) from BlackRock, Inc. (NYSE:BLK), The Vanguard Group, Inc., Thrivent Financial for Lutherans and others. Sep 03
Globus Medical, Inc. (NYSE:GMED) completed the acquisition of NuVasive, Inc. (NasdaqGS:NUVA) from BlackRock, Inc. (NYSE:BLK), The Vanguard Group, Inc., Thrivent Financial for Lutherans and others. Sep 02
Second quarter 2023 earnings released: EPS: US$0.14 (vs US$0.017 loss in 2Q 2022) Aug 08
NuVasive, Inc. Provides Sales Guidance for the Full Year 2023 Aug 03
NuVasive, Inc. to Report Q2, 2023 Results on Aug 02, 2023 Jul 25 See more updates
NuVasive, Inc.(NasdaqGS:NUVA) dropped from NASDAQ Composite Index Sep 06
Globus Medical, Inc. (NYSE:GMED) completed the acquisition of NuVasive, Inc. (NasdaqGS:NUVA) from BlackRock, Inc. (NYSE:BLK), The Vanguard Group, Inc., Thrivent Financial for Lutherans and others. Sep 03
Globus Medical, Inc. (NYSE:GMED) completed the acquisition of NuVasive, Inc. (NasdaqGS:NUVA) from BlackRock, Inc. (NYSE:BLK), The Vanguard Group, Inc., Thrivent Financial for Lutherans and others. Sep 02
Second quarter 2023 earnings released: EPS: US$0.14 (vs US$0.017 loss in 2Q 2022) Aug 08
NuVasive, Inc. Provides Sales Guidance for the Full Year 2023 Aug 03
NuVasive, Inc. to Report Q2, 2023 Results on Aug 02, 2023 Jul 25
NuVasive, Inc. Announces Resignation of Marc Rosenbaum as Vice President, Corporate Controller and Chief Accounting Officer May 12
NuVasive, Inc. Provides Sales Guidance for the Year 2023 May 11
NuVasive, Inc., Annual General Meeting, Jun 09, 2023 May 09
NuVasive, Inc. to Report Q1, 2023 Results on May 10, 2023 May 05 Globus Medical, Inc. (NYSE:GMED) entered into a definitive agreement to acquire NuVasive, Inc. (NasdaqGS:NUVA) for $3.1 billion.
NuVasive, Inc. to Report Q4, 2022 Results on Feb 22, 2023 Jan 31
Third quarter 2022 earnings released: US$0.038 loss per share (vs US$0.42 loss in 3Q 2021) Nov 11
NuVasive, Inc. Revises Earnings Guidance for the Year 2022 Nov 10
NuVasive, Inc. Launches Tube System and Excavation Micro for Posterior Spine Surgery Nov 08
NuVasive, Inc. to Report Q3, 2022 Results on Nov 09, 2022 Oct 26
Nuvasive Launches Reline Cervical for Posterior Cervical Fusion as Part of the C360 Portfolio Sep 29
NuVasive, Inc. Announces Departure of Massimo Calafiore as Executive Vice President and Chief Commercial Officer, Effective August 31, 2022 Aug 10
Second quarter 2022 earnings released: US$0.017 loss per share (vs US$0.035 profit in 2Q 2021) Aug 04
NuVasive, Inc. Revises Earnings Guidance for the Full Year of 2022 Aug 04
NuVasive, Inc. to Report Q2, 2022 Results on Aug 03, 2022 Jul 19
Now 22% undervalued Jun 07
NuVasive, Inc. Announces Management Changes May 14
Now 21% undervalued May 07
First quarter 2022 earnings released: EPS: US$0.37 (vs US$0.15 loss in 1Q 2021) May 06
NuVasive, Inc. Revises Earnings Guidance for the Full Year of 2022 May 05
NuVasive, Inc. to Report Q1, 2022 Results on May 04, 2022 Apr 21
Now 21% undervalued Apr 06
NuVasive, Inc., Annual General Meeting, May 11, 2022 Mar 31
NuVasive, Inc. Provides Earnings Guidance for the Full Year 2022 Feb 24
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Feb 24
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Feb 24
NuVasive, Inc. to Report Q4, 2021 Results on Feb 23, 2022 Feb 09
NuVasive, Inc. Appoints Andrew C. Morton as Senior Vice President and Chief Human Resources Officer, Effective February 7, 2022 Feb 01
Nuvasive Receives FDA Clearance for Expanded Indications of Use for Attrax Putty with Thoracolumbar Interbody Portfolio Jan 06
Third quarter 2021 earnings released: US$0.42 loss per share (vs US$0.12 profit in 3Q 2020) Nov 10
Senior VP & Chief Human Resources Officer Lucas Vitale has left the company Sep 23
NuVasive, Inc. Simplify Cervical Disc Data Publishes in International Journal of Spine Surgery Sep 10
High number of new directors Sep 02
Second quarter 2021 earnings released: EPS US$0.035 (vs US$0.98 loss in 2Q 2020) Jul 29
NuVasive, Inc. Launches Modulus ALIF 3D-Printed Porous Titanium Implant for Anterior Spine Surgery Jul 24
First quarter 2021 earnings released: US$0.15 loss per share (vs US$0.10 profit in 1Q 2020) May 07
New 90-day high: €51.00 Mar 03
NuVasive, Inc. Elects Siddhartha C. Kadia as Member of the Compensation Committee Mar 03
Full year 2020 earnings released: US$0.72 loss per share (vs US$1.26 profit in FY 2019) Feb 27
Revenue misses expectations Feb 27
NuVasive, Inc. (NasdaqGS:NUVA) entered into a definitive purchase agreement to acquire Simplify Medical, Inc. for approximately $200 million. Feb 26
NuVasive, Inc. to Report Q4, 2020 Results on Feb 25, 2021 Feb 12
New 90-day high: €48.80 Feb 10
NuVasive, Inc. Announces Appointment of Siddhartha Kadia to its Board of Directors Feb 02
NuVasive, Inc. Announces the Results of the Study Single Position Circumferential Fusion Improves Operative Efficiency, Reduces Complications and Length of Stay Compared with Traditional Circumferential Fusion Jan 08
New 90-day high: €48.00 Jan 07
NuVasive Unveils C360 Portfolio and Launches New Anterior Cervical Plate Dec 01
NuVasive, Inc. Expands Proprietary Porous PEEK Portfolio with Cohere XLIF Interbody Nov 19
Independent Director recently bought €82k worth of stock Nov 11
NuVasive's Thoracolumbar Interbody Portfolio Receives First Clearance in the US for the Treatment of Sagittal Deformities Nov 10
New 90-day low: €38.80 Oct 31
Third quarter earnings released Oct 30
Third-quarter earnings released: Revenue beats expectations Oct 30
NuVasive, Inc. to Report Q3, 2020 Results on Oct 29, 2020 Oct 20
NuVasive, Inc. Announces Executive Changes Oct 15
New 90-day low: €41.00 Sep 22
New 90-day low - €42.20 Aug 28
New 90-day low - €43.20 Aug 06
First half earnings released Aug 06 Shareholder Returns NK8 DE Medical Equipment DE Market 7D 2.8% 1.5% 2.6% 1Y -12.4% -6.0% 13.4%
See full shareholder returns
Return vs Market: NK8 underperformed the German Market which returned 8.6% over the past year.
Price Volatility Is NK8's price volatile compared to industry and market? NK8 volatility NK8 Average Weekly Movement n/a Medical Equipment Industry Average Movement 6.6% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.5% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: NK8 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine NK8's volatility change over the past year.
About the Company NuVasive, Inc., a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery. It provides surgical access instruments, including Maxcess integrated split-blade retractor system that enable less-invasive surgical techniques by minimizing soft tissue disruption during spine surgery; specialized spinal implants to advance spinal fusion by enhancing the osseointegration and biomechanical properties of implant materials, including porous titanium and porous polyetheretherketone; and fixation system that facilitates the preservation and restoration of patient alignment. The company also offers cervical total disc replacement technology for cervical spinal fusion surgery; neuromonitoring systems, which use proprietary software-driven nerve detection and avoidance technology, and its intraoperative neuromonitoring services and support; and Pulse platform, a software ecosystem that integrates multiple hardware technologies into a single, condensed footprint in the operating room.
Show more NuVasive, Inc. Fundamentals Summary How do NuVasive's earnings and revenue compare to its market cap? NK8 fundamental statistics Market cap €1.94b Earnings (TTM ) €26.41m Revenue (TTM ) €1.14b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) NK8 income statement (TTM ) Revenue US$1.23b Cost of Revenue US$347.50m Gross Profit US$878.73m Other Expenses US$850.28m Earnings US$28.45m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2023/09/02 13:48 End of Day Share Price 2023/08/31 00:00 Earnings 2023/06/30 Annual Earnings 2022/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources NuVasive, Inc. is covered by 39 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution null null Argus Research Company Jeffrey Johnson Baird Adam Feinstein Barclays
Show 36 more analysts 
